BioInvest In The News

Myovant: Drug Offers 'Best-in-Class' Potential
Esperion: Grand Slam in Cholesterol Reduction
Intrexon: Biotech, Biofuels & Fish Farming
Top Picks 2017: Madrigal
Top Picks 2017: The Medicines Company
Company Updates
Novavax (NVAX) 7-24-17

Novavax (NVAX) 7-24-17

BioInvest News – NVAX – Delivers Some Positive Phase II Immunogenicity Data In COPD…Investors Wanted an RSV Update – NVAX reported top line data from the Phase II older adult safety and immunogenicity trial (E205) demonstrated the benefit of adjuvant formulations and two-dose regimens in patients with RSV and chronic obstructive pulmonary disease (COPD).

Ionis (IONS) 5-15-17

Ionis (IONS) 5-15-17

BioInvest News – IONS – Reports Positive TTR Data, Safety/Patient Death Causes Concern – IONS reported positive Phase III data for inotersen (TTR-Rx) NEURO-TTR results in familial amyloid polyneuropathy (FAP) patients showing a statistically significant benefit in the two co-primary endpoints of modified Neuropathy Impairment Score (mNIS+7, p<0.0001) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN, P=0.0006) post 15 months of treatment.

Sangamo (SGMO) 5-10-17

Sangamo (SGMO) 5-10-17

Breaking News – Sangamo Therapeutics (SGMO) – PFE Global Deal for Hemophilia A Has Many Positive Implications – In a very competitive bidding process SGMO has inked a significant global partnership with Pfizer, who brings a wealth of value to SGMO, and notably validates the latter company’s gene therapy platform.